Skip to main content

Table 8 Efficacy or effectiveness of vaccination against human papillomavirus in males: anogenital lesions in participants who were seronegative and PCR-negative at enrolment

From: Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review

Study

Design

No. of events/no. of participants

Unadjusted estimate (95% CI)

Confounder-adjusted estimate (95% CI)

VE (95% CI)

Vaccine

Control

Condylomata acuminata

Genital

  Giuliano et al. (2011) [32]a

RCT

3/2830.9 pyrs

28/2813.9 pyrs

NR

NA

89.4% (65.5–97.9%)

Anal

  Palefsky et al. (2011) [33]a

RCT

0/386.8 pyrs

6/418.2 pyrs

NR

NA

100% (8.2–100%)

Anal intraepithelial neoplasia grade 2

 Palefsky et al. (2011) [33]a

RCT

2/384.5 pyrs

9/418.6 pyrs

NR

NA

75.8% (−16.9 to 97.5%)

Anal intraepithelial neoplasia grade 3

 Palefsky et al. (2011) [33]a

RCT

2/385.4 pyrs

6/419.7 pyrs

NR

NA

63.7 (−103 to 96.4%)

Anal cancer

 Palefsky et al. (2011) [33]

RCT

0/386.8 pyrs

0/421.1 pyrs

NR

NA

Penile, perineal or perianal neoplasia grade 2 or 3

 Giuliano et al. (2011) [32]a

RCT

0/2833.3 pyrs

1/2824.7 pyrs

NR

NA

100% (− 3788.2 to 100%)

Penile, perineal or perianal cancer

 Giuliano et al. (2011) [32]

RCT

0/2833.3 pyrs

0/2826.2 pyrs

NR

NA

  1. NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
  2. aVE as reported in the primary study